Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy.
Giorgio Lorenzo ColomboMaria Chiara ValentinoAlessandra FabiMaria Vittoria DieciMauro CaruggiGiacomo Matteo BrunoGloria LombardiSergio Di MatteoPublished in: Therapeutics and clinical risk management (2023)
From the Italian perspective, a cost-saving profile associated with the use of PAL+FUL for the management of advanced/metastatic HR+/HER2- breast cancer compared to RIB+FUL and ABM+FUL emerged.